nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—Dactinomycin—testicular cancer	0.158	0.193	CbGbCtD
Linagliptin—CYP3A4—Ifosfamide—testicular cancer	0.112	0.137	CbGbCtD
Linagliptin—ABCB1—Vinblastine—testicular cancer	0.099	0.121	CbGbCtD
Linagliptin—ABCB1—Cisplatin—testicular cancer	0.0907	0.111	CbGbCtD
Linagliptin—ABCB1—Etoposide—testicular cancer	0.0892	0.109	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—testicular cancer	0.0608	0.0744	CbGbCtD
Linagliptin—CYP3A4—Vinblastine—testicular cancer	0.0593	0.0725	CbGbCtD
Linagliptin—ABCB1—Methotrexate—testicular cancer	0.0589	0.0721	CbGbCtD
Linagliptin—CYP3A4—Etoposide—testicular cancer	0.0534	0.0654	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—testicular cancer	0.0364	0.0446	CbGbCtD
Linagliptin—Bronchial hyperreactivity—Methotrexate—testicular cancer	0.00606	0.0332	CcSEcCtD
Linagliptin—Diabetic—Methotrexate—testicular cancer	0.00474	0.026	CcSEcCtD
Linagliptin—Skin exfoliation—Bleomycin—testicular cancer	0.00374	0.0205	CcSEcCtD
Linagliptin—Infection—Carboplatin—testicular cancer	0.00348	0.0191	CcSEcCtD
Linagliptin—Skin exfoliation—Ifosfamide—testicular cancer	0.00319	0.0175	CcSEcCtD
Linagliptin—Skin exfoliation—Cisplatin—testicular cancer	0.00275	0.0151	CcSEcCtD
Linagliptin—Skin exfoliation—Etoposide—testicular cancer	0.00252	0.0138	CcSEcCtD
Linagliptin—Pain in extremity—Ifosfamide—testicular cancer	0.00243	0.0133	CcSEcCtD
Linagliptin—Pancreatitis—Ifosfamide—testicular cancer	0.00206	0.0113	CcSEcCtD
Linagliptin—Hyperlipidaemia—Epirubicin—testicular cancer	0.00205	0.0112	CcSEcCtD
Linagliptin—Angioedema—Chlorambucil—testicular cancer	0.00202	0.0111	CcSEcCtD
Linagliptin—Hyperlipidaemia—Doxorubicin—testicular cancer	0.0019	0.0104	CcSEcCtD
Linagliptin—Nasopharyngitis—Cisplatin—testicular cancer	0.00187	0.0102	CcSEcCtD
Linagliptin—Infestation NOS—Ifosfamide—testicular cancer	0.00187	0.0102	CcSEcCtD
Linagliptin—Infestation—Ifosfamide—testicular cancer	0.00187	0.0102	CcSEcCtD
Linagliptin—Infection—Chlorambucil—testicular cancer	0.00179	0.00981	CcSEcCtD
Linagliptin—Pancreatitis—Cisplatin—testicular cancer	0.00177	0.00971	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00156	0.00853	CcSEcCtD
Linagliptin—Immune system disorder—Ifosfamide—testicular cancer	0.00152	0.00831	CcSEcCtD
Linagliptin—Mediastinal disorder—Ifosfamide—testicular cancer	0.00151	0.00829	CcSEcCtD
Linagliptin—Skin exfoliation—Methotrexate—testicular cancer	0.00151	0.00827	CcSEcCtD
Linagliptin—Cough—Bleomycin—testicular cancer	0.00149	0.00817	CcSEcCtD
Linagliptin—Infestation—Etoposide—testicular cancer	0.00148	0.00809	CcSEcCtD
Linagliptin—Infestation NOS—Etoposide—testicular cancer	0.00148	0.00809	CcSEcCtD
Linagliptin—Malnutrition—Ifosfamide—testicular cancer	0.00146	0.00801	CcSEcCtD
Linagliptin—Myalgia—Bleomycin—testicular cancer	0.00146	0.00797	CcSEcCtD
Linagliptin—Urticaria—Chlorambucil—testicular cancer	0.00143	0.00785	CcSEcCtD
Linagliptin—Constipation—Vinblastine—testicular cancer	0.00141	0.00774	CcSEcCtD
Linagliptin—Skin exfoliation—Epirubicin—testicular cancer	0.00141	0.00774	CcSEcCtD
Linagliptin—Anaphylactic shock—Bleomycin—testicular cancer	0.0014	0.00764	CcSEcCtD
Linagliptin—Infection—Bleomycin—testicular cancer	0.00139	0.00759	CcSEcCtD
Linagliptin—Myalgia—Dactinomycin—testicular cancer	0.00136	0.00744	CcSEcCtD
Linagliptin—Angioedema—Ifosfamide—testicular cancer	0.00134	0.00731	CcSEcCtD
Linagliptin—Hypersensitivity—Chlorambucil—testicular cancer	0.00133	0.00728	CcSEcCtD
Linagliptin—Diabetes mellitus—Methotrexate—testicular cancer	0.00132	0.00723	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—testicular cancer	0.00131	0.00716	CcSEcCtD
Linagliptin—Immune system disorder—Cisplatin—testicular cancer	0.00131	0.00716	CcSEcCtD
Linagliptin—Mediastinal disorder—Cisplatin—testicular cancer	0.00131	0.00714	CcSEcCtD
Linagliptin—Infection—Dactinomycin—testicular cancer	0.00129	0.00708	CcSEcCtD
Linagliptin—Cough—Ifosfamide—testicular cancer	0.00128	0.00699	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00127	0.00696	CcSEcCtD
Linagliptin—Malnutrition—Cisplatin—testicular cancer	0.00126	0.0069	CcSEcCtD
Linagliptin—Arthralgia—Ifosfamide—testicular cancer	0.00124	0.00682	CcSEcCtD
Linagliptin—Myalgia—Ifosfamide—testicular cancer	0.00124	0.00682	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00124	0.00677	CcSEcCtD
Linagliptin—Diabetes mellitus—Epirubicin—testicular cancer	0.00124	0.00677	CcSEcCtD
Linagliptin—Diarrhoea—Chlorambucil—testicular cancer	0.00123	0.00676	CcSEcCtD
Linagliptin—Hypersensitivity—Vinblastine—testicular cancer	0.00122	0.00667	CcSEcCtD
Linagliptin—Immune system disorder—Etoposide—testicular cancer	0.0012	0.00656	CcSEcCtD
Linagliptin—Mediastinal disorder—Etoposide—testicular cancer	0.0012	0.00655	CcSEcCtD
Linagliptin—Anaphylactic shock—Ifosfamide—testicular cancer	0.00119	0.00653	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00119	0.0065	CcSEcCtD
Linagliptin—Infection—Ifosfamide—testicular cancer	0.00119	0.00649	CcSEcCtD
Linagliptin—Skin disorder—Ifosfamide—testicular cancer	0.00116	0.00635	CcSEcCtD
Linagliptin—Diabetes mellitus—Doxorubicin—testicular cancer	0.00114	0.00626	CcSEcCtD
Linagliptin—Diarrhoea—Vinblastine—testicular cancer	0.00113	0.00619	CcSEcCtD
Linagliptin—Back pain—Etoposide—testicular cancer	0.00112	0.00612	CcSEcCtD
Linagliptin—Urticaria—Bleomycin—testicular cancer	0.00111	0.00607	CcSEcCtD
Linagliptin—Hypoglycaemia—Epirubicin—testicular cancer	0.0011	0.00603	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00109	0.00595	CcSEcCtD
Linagliptin—Pain in extremity—Epirubicin—testicular cancer	0.00107	0.00588	CcSEcCtD
Linagliptin—Myalgia—Cisplatin—testicular cancer	0.00107	0.00588	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00107	0.00583	CcSEcCtD
Linagliptin—Headache—Vinblastine—testicular cancer	0.00104	0.00567	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00103	0.00564	CcSEcCtD
Linagliptin—Anaphylactic shock—Cisplatin—testicular cancer	0.00103	0.00563	CcSEcCtD
Linagliptin—Hypersensitivity—Bleomycin—testicular cancer	0.00103	0.00563	CcSEcCtD
Linagliptin—Infection—Cisplatin—testicular cancer	0.00102	0.0056	CcSEcCtD
Linagliptin—Constipation—Ifosfamide—testicular cancer	0.00102	0.00559	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—testicular cancer	0.00102	0.00558	CcSEcCtD
Linagliptin—Cough—Etoposide—testicular cancer	0.00101	0.00552	CcSEcCtD
Linagliptin—Skin disorder—Cisplatin—testicular cancer	0.000999	0.00547	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—testicular cancer	0.000995	0.00545	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000976	0.00535	CcSEcCtD
Linagliptin—Pancreatitis—Methotrexate—testicular cancer	0.000973	0.00533	CcSEcCtD
Linagliptin—Nasopharyngitis—Epirubicin—testicular cancer	0.000961	0.00526	CcSEcCtD
Linagliptin—Hypersensitivity—Dactinomycin—testicular cancer	0.000959	0.00525	CcSEcCtD
Linagliptin—Urticaria—Ifosfamide—testicular cancer	0.000948	0.00519	CcSEcCtD
Linagliptin—Anaphylactic shock—Etoposide—testicular cancer	0.000943	0.00516	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000937	0.00513	CcSEcCtD
Linagliptin—Infection—Etoposide—testicular cancer	0.000936	0.00513	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000923	0.00505	CcSEcCtD
Linagliptin—Skin disorder—Etoposide—testicular cancer	0.000916	0.00501	CcSEcCtD
Linagliptin—Pancreatitis—Epirubicin—testicular cancer	0.000911	0.00499	CcSEcCtD
Linagliptin—Diarrhoea—Dactinomycin—testicular cancer	0.000891	0.00488	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—testicular cancer	0.000889	0.00487	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000888	0.00486	CcSEcCtD
Linagliptin—Infestation NOS—Methotrexate—testicular cancer	0.000885	0.00485	CcSEcCtD
Linagliptin—Infestation—Methotrexate—testicular cancer	0.000885	0.00485	CcSEcCtD
Linagliptin—Rash—Bleomycin—testicular cancer	0.00088	0.00482	CcSEcCtD
Linagliptin—Dermatitis—Bleomycin—testicular cancer	0.00088	0.00482	CcSEcCtD
Linagliptin—Hypersensitivity—Ifosfamide—testicular cancer	0.000879	0.00481	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000863	0.00473	CcSEcCtD
Linagliptin—Weight increased—Epirubicin—testicular cancer	0.000846	0.00463	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—testicular cancer	0.000843	0.00461	CcSEcCtD
Linagliptin—Infestation NOS—Epirubicin—testicular cancer	0.000828	0.00454	CcSEcCtD
Linagliptin—Infestation—Epirubicin—testicular cancer	0.000828	0.00454	CcSEcCtD
Linagliptin—Rash—Dactinomycin—testicular cancer	0.000821	0.0045	CcSEcCtD
Linagliptin—Diarrhoea—Ifosfamide—testicular cancer	0.000817	0.00447	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Etoposide—testicular cancer	0.000814	0.00445	CcSEcCtD
Linagliptin—Constipation—Etoposide—testicular cancer	0.000806	0.00441	CcSEcCtD
Linagliptin—Urinary tract infection—Epirubicin—testicular cancer	0.000805	0.00441	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000799	0.00437	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—testicular cancer	0.000782	0.00428	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—testicular cancer	0.000767	0.0042	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—testicular cancer	0.000767	0.0042	CcSEcCtD
Linagliptin—Hypersensitivity—Cisplatin—testicular cancer	0.000758	0.00415	CcSEcCtD
Linagliptin—Rash—Ifosfamide—testicular cancer	0.000752	0.00412	CcSEcCtD
Linagliptin—Dermatitis—Ifosfamide—testicular cancer	0.000752	0.00412	CcSEcCtD
Linagliptin—Urticaria—Etoposide—testicular cancer	0.000749	0.0041	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—testicular cancer	0.000745	0.00408	CcSEcCtD
Linagliptin—Immune system disorder—Methotrexate—testicular cancer	0.000718	0.00393	CcSEcCtD
Linagliptin—Mediastinal disorder—Methotrexate—testicular cancer	0.000716	0.00392	CcSEcCtD
Linagliptin—Diarrhoea—Cisplatin—testicular cancer	0.000704	0.00385	CcSEcCtD
Linagliptin—Hypersensitivity—Etoposide—testicular cancer	0.000694	0.0038	CcSEcCtD
Linagliptin—Malnutrition—Methotrexate—testicular cancer	0.000692	0.00379	CcSEcCtD
Linagliptin—Immune system disorder—Epirubicin—testicular cancer	0.000672	0.00368	CcSEcCtD
Linagliptin—Mediastinal disorder—Epirubicin—testicular cancer	0.00067	0.00367	CcSEcCtD
Linagliptin—Back pain—Methotrexate—testicular cancer	0.000669	0.00366	CcSEcCtD
Linagliptin—Rash—Cisplatin—testicular cancer	0.000649	0.00355	CcSEcCtD
Linagliptin—Dermatitis—Cisplatin—testicular cancer	0.000648	0.00355	CcSEcCtD
Linagliptin—Malnutrition—Epirubicin—testicular cancer	0.000647	0.00354	CcSEcCtD
Linagliptin—Diarrhoea—Etoposide—testicular cancer	0.000645	0.00353	CcSEcCtD
Linagliptin—Back pain—Epirubicin—testicular cancer	0.000626	0.00343	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—testicular cancer	0.000622	0.0034	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—testicular cancer	0.00062	0.00339	CcSEcCtD
Linagliptin—Cough—Methotrexate—testicular cancer	0.000604	0.0033	CcSEcCtD
Linagliptin—Malnutrition—Doxorubicin—testicular cancer	0.000599	0.00328	CcSEcCtD
Linagliptin—Rash—Etoposide—testicular cancer	0.000594	0.00325	CcSEcCtD
Linagliptin—Dermatitis—Etoposide—testicular cancer	0.000594	0.00325	CcSEcCtD
Linagliptin—Headache—Etoposide—testicular cancer	0.00059	0.00323	CcSEcCtD
Linagliptin—Myalgia—Methotrexate—testicular cancer	0.000589	0.00322	CcSEcCtD
Linagliptin—Arthralgia—Methotrexate—testicular cancer	0.000589	0.00322	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000585	0.0032	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—testicular cancer	0.000579	0.00317	CcSEcCtD
Linagliptin—Cough—Epirubicin—testicular cancer	0.000565	0.00309	CcSEcCtD
Linagliptin—Anaphylactic shock—Methotrexate—testicular cancer	0.000565	0.00309	CcSEcCtD
Linagliptin—Infection—Methotrexate—testicular cancer	0.000561	0.00307	CcSEcCtD
Linagliptin—Myalgia—Epirubicin—testicular cancer	0.000551	0.00302	CcSEcCtD
Linagliptin—Arthralgia—Epirubicin—testicular cancer	0.000551	0.00302	CcSEcCtD
Linagliptin—Skin disorder—Methotrexate—testicular cancer	0.000548	0.003	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000547	0.003	CcSEcCtD
Linagliptin—Anaphylactic shock—Epirubicin—testicular cancer	0.000528	0.00289	CcSEcCtD
Linagliptin—Infection—Epirubicin—testicular cancer	0.000525	0.00287	CcSEcCtD
Linagliptin—Cough—Doxorubicin—testicular cancer	0.000523	0.00286	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000514	0.00282	CcSEcCtD
Linagliptin—Skin disorder—Epirubicin—testicular cancer	0.000513	0.00281	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—testicular cancer	0.00051	0.00279	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—testicular cancer	0.00051	0.00279	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000506	0.00277	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—testicular cancer	0.000489	0.00268	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000487	0.00267	CcSEcCtD
Linagliptin—Infection—Doxorubicin—testicular cancer	0.000486	0.00266	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000481	0.00264	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—testicular cancer	0.000475	0.0026	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000456	0.0025	CcSEcCtD
Linagliptin—Constipation—Epirubicin—testicular cancer	0.000452	0.00247	CcSEcCtD
Linagliptin—Urticaria—Methotrexate—testicular cancer	0.000449	0.00246	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000445	0.00244	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000422	0.00231	CcSEcCtD
Linagliptin—Urticaria—Epirubicin—testicular cancer	0.00042	0.0023	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—testicular cancer	0.000418	0.00229	CcSEcCtD
Linagliptin—Hypersensitivity—Methotrexate—testicular cancer	0.000416	0.00228	CcSEcCtD
Linagliptin—Hypersensitivity—Epirubicin—testicular cancer	0.000389	0.00213	CcSEcCtD
Linagliptin—Urticaria—Doxorubicin—testicular cancer	0.000388	0.00213	CcSEcCtD
Linagliptin—Diarrhoea—Methotrexate—testicular cancer	0.000386	0.00211	CcSEcCtD
Linagliptin—Diarrhoea—Epirubicin—testicular cancer	0.000361	0.00198	CcSEcCtD
Linagliptin—Hypersensitivity—Doxorubicin—testicular cancer	0.00036	0.00197	CcSEcCtD
Linagliptin—Rash—Methotrexate—testicular cancer	0.000356	0.00195	CcSEcCtD
Linagliptin—Dermatitis—Methotrexate—testicular cancer	0.000356	0.00195	CcSEcCtD
Linagliptin—Headache—Methotrexate—testicular cancer	0.000354	0.00194	CcSEcCtD
Linagliptin—Diarrhoea—Doxorubicin—testicular cancer	0.000334	0.00183	CcSEcCtD
Linagliptin—Rash—Epirubicin—testicular cancer	0.000333	0.00182	CcSEcCtD
Linagliptin—Dermatitis—Epirubicin—testicular cancer	0.000333	0.00182	CcSEcCtD
Linagliptin—Headache—Epirubicin—testicular cancer	0.000331	0.00181	CcSEcCtD
Linagliptin—Rash—Doxorubicin—testicular cancer	0.000308	0.00169	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—testicular cancer	0.000308	0.00169	CcSEcCtD
Linagliptin—Headache—Doxorubicin—testicular cancer	0.000306	0.00168	CcSEcCtD
